Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Neurizon Therapeutics Limited Australia New York

View original content:https://www.prnewswire.co.uk/news-releases/neurizons-nuz-001-reduces-aggregation-of-key-als-disease-target-tdp-43-in-preclinical-study-302309581.html